Aifa puts a brake on gastroprotectors (for health and for the budget)
The overuse of proton pump inhibitors, commonly known as gastroprotectors, has led Aifa to redefine the boundaries of their use for both health and economic reasons. In 2024, public pharmaceutical spending on these products reached 619.80 million euros, and it is estimated that 10.5 million Italians take them. Facts, figures, and comments.
